Use of the 22C3 anti–PD | 合法醫療器材資訊網

(A)ThePD-L122C3pharmDxkitontheDakoASL48platform;(B)optimisedLDT(primaryantibodydilution1:50,30-minuteincubation);(C)LDTusingprimary ...

PD-L1 staining patterns on NSCLC specimens using the 22C3 antibody concentrate on the VENTANA BenchMark ULTRA platform (LDT) compared with the PD-L1 IHC 22C3 pharmDx kit on the Dako ASL48 platform (gold standard).

(A) The PD-L1 IHC 22C3 pharmDx kit on the Dako ASL48 platform; (B) optimised LDT (CC1 64 minutes, 22C3 primary antibody dilution 1:50, OptiView amplification 12 minutes); (C) CC1 32 minutes, primary antibody dilution 1:50, OptiView amplification 12 minutes; (D) CC1 64 minutes, primary antibody dilution 1:50, OptiView amplification 4 minutes; (E) CC1 32 minutes, primary antibody dilution 1:100, OptiView amplification 12 minutes; (F) CC1 64 minutes, primary antibody dilution 1:100, OptiView amplification 12 minutes. Original magnification 5×. Inserts, original magnification 40×. PD-L1, programmed death ligand 1; NSCLC, non–small cell lung cancer; ASL48, Autostainer Link 48; LDT, l...